HRP20220231T1 - Spojevi i postupci za liječenje bakterijskih infekcija - Google Patents

Spojevi i postupci za liječenje bakterijskih infekcija Download PDF

Info

Publication number
HRP20220231T1
HRP20220231T1 HRP20220231TT HRP20220231T HRP20220231T1 HR P20220231 T1 HRP20220231 T1 HR P20220231T1 HR P20220231T T HRP20220231T T HR P20220231TT HR P20220231 T HRP20220231 T HR P20220231T HR P20220231 T1 HRP20220231 T1 HR P20220231T1
Authority
HR
Croatia
Prior art keywords
alkyl
image
optionally substituted
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
HRP20220231TT
Other languages
English (en)
Croatian (hr)
Inventor
Janelle Comita-Prevoir
Thomas Francois Durand-Reville
Satenig GULER
Jan Romero
Mark Sylvester
Ruben Tommasi
Camilo VELEZ-VEGA
Xiaoyun Wu
Jing Zhang
Original Assignee
Entasis Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entasis Therapeutics, Inc. filed Critical Entasis Therapeutics, Inc.
Publication of HRP20220231T1 publication Critical patent/HRP20220231T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HRP20220231TT 2017-05-08 2018-05-08 Spojevi i postupci za liječenje bakterijskih infekcija HRP20220231T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762502867P 2017-05-08 2017-05-08
PCT/US2018/031593 WO2018208769A1 (en) 2017-05-08 2018-05-08 Compounds and methods for treating bacterial infections
EP18726702.6A EP3630111B1 (en) 2017-05-08 2018-05-08 Compounds and methods for treating bacterial infections

Publications (1)

Publication Number Publication Date
HRP20220231T1 true HRP20220231T1 (hr) 2022-04-29

Family

ID=62223332

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20220231TT HRP20220231T1 (hr) 2017-05-08 2018-05-08 Spojevi i postupci za liječenje bakterijskih infekcija

Country Status (27)

Country Link
US (1) US11046694B2 (https=)
EP (1) EP3630111B1 (https=)
JP (1) JP7058322B2 (https=)
KR (1) KR102611447B1 (https=)
CN (1) CN110709081B (https=)
AU (1) AU2018266640B2 (https=)
CY (1) CY1125340T1 (https=)
DK (1) DK3630111T3 (https=)
EA (1) EA038393B1 (https=)
ES (1) ES2907858T3 (https=)
HR (1) HRP20220231T1 (https=)
HU (1) HUE057592T2 (https=)
IL (1) IL270380B (https=)
LT (1) LT3630111T (https=)
MA (1) MA48743A (https=)
MX (1) MX385203B (https=)
MY (1) MY201377A (https=)
NZ (1) NZ758200A (https=)
PE (1) PE20200333A1 (https=)
PH (1) PH12019502509A1 (https=)
PL (1) PL3630111T3 (https=)
PT (1) PT3630111T (https=)
SG (1) SG11201909443YA (https=)
SI (1) SI3630111T1 (https=)
SM (1) SMT202200110T1 (https=)
TW (1) TWI791018B (https=)
WO (1) WO2018208769A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP3833665B1 (en) 2018-08-09 2023-07-19 Antabio SAS Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN111675641B (zh) * 2020-06-04 2023-09-08 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) 单环β-内酰胺类化合物、单环内酰胺类化合物盐及其制备方法
CN115605480B (zh) 2021-05-07 2024-04-05 宁夏农林科学院 磺酰脒取代的化合物及其作为β-内酰胺酶抑制剂的用途
US11814385B2 (en) 2021-06-25 2023-11-14 University Of South Florida Small molecule inhibitors targeting Clostridioides difficile sporulation
AU2024346059A1 (en) * 2023-09-19 2026-04-02 Entasis Therapeutics Inc. Compounds and methods for treating bacterial infections

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ282567B6 (cs) 1993-12-29 1997-08-13 Pfizer Inc. Diazabicyklické sloučeniny a farmaceutické prostředky na jejich bázi
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2848210B1 (fr) 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
US7439253B2 (en) * 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
US7507727B2 (en) * 2003-04-07 2009-03-24 Cylene Pharmaceuticals, Inc. Substituted quinobenzoxazine analogs and methods of using thereof
FR2914923B1 (fr) 2007-04-12 2013-06-14 Novexel Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens.
WO2009091856A2 (en) 2008-01-18 2009-07-23 Merck & Co., Inc. Beta-lactamase inhibitors
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
EP2921559A1 (en) 2008-06-19 2015-09-23 Astra Zeneca Holding France Use of (1r,2s,5r) 1,6-diazabicyclo [3.2.1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2937034B1 (fr) * 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2936951B1 (fr) 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
WO2013014497A1 (en) 2011-07-26 2013-01-31 Wockhardt Limited Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
NZ616806A (en) 2011-07-26 2015-03-27 Wockhardt Ltd Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
MX348974B (es) 2011-08-27 2017-07-04 Wockhardt Ltd Derivados 1,6 - diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
CA2845108C (en) * 2011-08-30 2015-06-16 Wockhardt Limited 1,6-diazabicyclo[3,2,1]octan-7-one derivatives and their use in the treatment of bacterial infections
CA2846107C (en) 2011-09-13 2016-06-21 Wockhardt Limited Nitrogen containing compounds and their use
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
EP2814483A2 (en) 2012-02-15 2014-12-24 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
WO2013149136A1 (en) 2012-03-30 2013-10-03 Cubist Pharmaceuticals, Inc. ISOXAZOLE β-LACTAMASE INHIBITORS
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
US8940897B2 (en) 2012-03-30 2015-01-27 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitors
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
HUE046893T2 (hu) 2012-05-30 2020-04-28 Meiji Seika Pharma Co Ltd Új ß-laktamáz inhibitor és eljárás elõállítására
RU2614418C2 (ru) 2012-08-25 2017-03-28 Вокхардт Лимитед Производные 1,6-диазабицикло[3.2.1]октан-7-она и их применение для лечения бактериальных инфекций
US20150258072A1 (en) 2012-09-03 2015-09-17 Wockhardt Limited Antibacterial compositions
EP2953626A1 (en) 2013-02-06 2015-12-16 Astrazeneca AB Combination therapy for the treatment of nosocomial pneumonia
WO2014141132A1 (en) * 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
JP6764862B2 (ja) 2014-11-17 2020-10-07 エンタシス・セラピューティックス・リミテッド 耐性細菌感染症の治療のための併用療法
DK3512851T3 (en) 2016-09-16 2022-10-17 Entasis Therapeutics Ltd Beta-lactamase inhibitor compounds

Also Published As

Publication number Publication date
MA48743A (fr) 2020-04-08
MY201377A (en) 2024-02-21
HUE057592T2 (hu) 2022-05-28
SI3630111T1 (sl) 2022-05-31
ES2907858T3 (es) 2022-04-26
SMT202200110T1 (it) 2022-05-12
KR20200005586A (ko) 2020-01-15
EP3630111B1 (en) 2021-11-24
MX385203B (es) 2025-03-14
WO2018208769A1 (en) 2018-11-15
JP7058322B2 (ja) 2022-04-21
NZ758200A (en) 2025-12-19
CY1125340T1 (el) 2024-02-16
AU2018266640B2 (en) 2022-03-03
EP3630111A1 (en) 2020-04-08
TW201843152A (zh) 2018-12-16
BR112019023130A2 (pt) 2020-05-26
CA3059773A1 (en) 2018-11-15
CN110709081A (zh) 2020-01-17
CN110709081B (zh) 2023-09-22
PH12019502509A1 (en) 2020-07-13
PE20200333A1 (es) 2020-02-14
AU2018266640A1 (en) 2019-11-07
JP2020519687A (ja) 2020-07-02
DK3630111T3 (en) 2022-03-14
TWI791018B (zh) 2023-02-01
PL3630111T3 (pl) 2022-05-23
EA201992370A1 (ru) 2020-03-10
MX2019013291A (es) 2020-01-15
KR102611447B1 (ko) 2023-12-06
US11046694B2 (en) 2021-06-29
SG11201909443YA (en) 2019-11-28
IL270380B (en) 2022-06-01
LT3630111T (lt) 2022-03-10
PT3630111T (pt) 2022-03-01
US20200165251A1 (en) 2020-05-28
EA038393B1 (ru) 2021-08-20

Similar Documents

Publication Publication Date Title
HRP20220231T1 (hr) Spojevi i postupci za liječenje bakterijskih infekcija
GEAP202415986A (en) Substituted aminoquinolones as dgkalpha inhibitors for immune activation
HRP20251156T1 (hr) Supstituirani makrociklični spojevi i srodni postupci liječenja
ME02815B (me) Biciklična heterociklična jedinjenja kao inhibitori protein tirozin kinaze
HRP20241197T1 (hr) Makrociklični spojevi i primjene istih
HRP20170154T1 (hr) Analozi antibakterijskog aminoglikozida
ME02875B (me) Inhibitori hcv polimeraze
HRP20241540T1 (hr) Pirolotriazinski spojevi koji djeluju kao inhibitor mnk
ME02373B (me) Biciklična heterociklična jedinjenja kao inhibitori protein tirozin kinaze
HRP20221112T1 (hr) Derivati benzodiazepina kao inhibitori rsv
ATE526341T1 (de) Makrozyklische verbindungen als antivirale mittel
HRP20210895T1 (hr) Inhibitori hpk1 i metode za njihovo korištenje
ME02835B (me) Antivirusna rsv jedinjenja
AR073760A1 (es) Derivados heterociclicos y metodos de uso de los mismos
BR112014000563A2 (pt) composto, composição farmacêutica, e, uso do composto
MX2019004578A (es) Oxisteroles y metodos de uso de los mismos.
ME02453B (me) Inhibitori protein kinaze
WO2020113213A3 (en) Cyclic pantetheine derivatives and uses thereof
AR107864A1 (es) ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS
SE0202133D0 (sv) Novel compounds
PE20090648A1 (es) Compuestos para el tratamiento de la hepatitis c
GEP20207128B (en) Aminothiazole derivatives useful as antiviral agents
MX2010004293A (es) Derivados de 6-aril/heteroalquiloxi benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nuevo uso principalmente como inhibidores de cmet.
AR054482A1 (es) Derivados de azetidinona para el tratamiento de hiperlipidemias
AR065014A1 (es) Derivado de heterocicliden-n-(aril)acetamida